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Objectives: The aim of this study was to assess the current evidence for long-acting β
2
-agonist 
(LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) in the 
treatment of COPD.
Materials and methods: A systematic literature search of randomized controlled trials pub-
lished in English up to September 2017 of LABA/LAMA FDCs vs LABA or LAMA or LABA/
inhaled corticosteroid (ICS) FDCs in COPD patients was performed using PubMed, Embase, 
Scopus, and Google Scholar. Outcomes including forced expiratory volume in 1 second (FEV
1
), 
Transition Dyspnea Index (TDI) scores, St George’s Respiratory Questionnaire (SGRQ) scores, 
exacerbations, exercise tolerance (endurance time [ET]), inspiratory capacity (IC), and rescue 
medication use were evaluated.
Results: In total, 27 studies were included in the review. LABA/LAMA FDCs significantly 
improved lung function (FEV
1
) at 12 weeks compared with LABA or LAMA or LABA/ICS. 
These effects were maintained over time. Significant improvements with LABA/LAMA FDCs 
vs each evaluated comparator were also observed in TDI and SGRQ scores, even if significant 
differences between different LABA/LAMA FDCs were detected. Only the LABA/LAMA FDC 
indacaterol/glycopyrronium has shown superiority vs LAMA and LABA/ICS for reducing exac-
erbation rates, while olodaterol/tiotropium and indacaterol/glycopyrronium have been shown to 
improve ET and IC vs the active comparators. Rescue medication use was significantly reduced 
by LABA/LAMA FDCs vs the evaluated comparators. LABA/LAMA FDCs were safe, with no 
increase in the risk of adverse events with LABA/LAMA FDCs vs the monocomponents.
Conclusion: Evidence supporting the efficacy of LABA/LAMA FDCs for COPD is heteroge-
neous, particularly for TDI and SGRQ scores, exacerbation rates, ET, and IC. So far, indacaterol/
glycopyrronium is the LABA/LAMA FDC that has the strongest evidence for superiority vs 
LABA, LAMA, and LABA/ICS FDCs across the evaluated outcomes. LABA/LAMA FDCs were 
safe; however, more data should be collected in a real-world setting to confirm their safety.
Keywords: LABA, LAMA, fixed-dose combination, COPD, systematic review
Introduction
COPD is a chronic disease characterized by not fully reversible, commonly progressive 
airflow limitation. According to the WHO estimates, 65 million people have moderate-
to-severe COPD worldwide. In 2005, COPD-related deaths accounted for 5% of 
worldwide deaths; the data certainly underestimated as the most epidemiological 
data that originate exclusively from high-income countries.1 Based on current figures, 
WHO predicts a 30% increase in COPD deaths over the next 10 years, which will 
make COPD the third highest cause of death worldwide by 2030.1
Guidelines and recommendations aim at assisting physicians during the process 
of diagnosis and disease management so that any single COPD patient may receive 
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the most appropriate medical care by adhering to evidence-
based medicine. Bronchodilators are the mainstay of COPD 
treatment. Long-acting β
2
-agonists (LABAs) or ultra-LABAs 
and long-acting muscarinic antagonists (LAMAs) are the 
preferred options for patients at different stages of the disease. 
Indeed, the most recent update of the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) recommenda-
tions states that 1) LABAs and LAMAs significantly improve 
lung function and dyspnea health status, and reduce exacerba-
tion rates, and 2) combination treatment with LABA/LAMA 
increases forced expiratory volume in 1 second (FEV
1
) and 
reduce COPD symptoms compared with monotherapy.2 Both 
statements are provided with the highest strength of recom-
mendation according to the level of evidence (level A).2 
Benefits of LABA/LAMA fixed-dose combinations (FDCs) 
are widely reported;3–5 however, the availability of different 
FDC options approved for the treatment of COPD and the 
absence of head-to-head studies between all the available 
LABA/LAMA FDCs make choosing the most appropriate 
option difficult.
Therapeutic choice always depends on the evaluation of 
biological characteristics of the disease, symptoms, previous 
therapies and responses to them, health status, and last but 
not least patient preference. Therefore, the optimal therapy 
is the one drawn on the medical history of each patient. 
However, results from clinical trials, clinical practice, and 
guidelines are essential for an evidence-based medicine 
approach.
Patients’ characteristics such as age, cognitive status, 
visual acuity, manual dexterity, manual strength, and coor-
dination may influence the correct use of inhaler devices and, 
thus, the efficacy of inhaled medications. In fact, for several 
patients using a nebulizer, a pressurized metered dose inhaler 
or a dry powder inhaler device provides an easy-to-use and 
cost-effective therapy.6
This review will systematically and critically examine 
the available evidence on marketed LABA/LAMA FDCs 
or those under development in terms of clinical relevance 
for the management of COPD.
Materials and methods
Review questions
Is the evidence for the efficacy of LABA/LAMA FDCs for 
COPD the same across the literature?
Are the numbers of randomized controlled trials (RCTs) 
on LABA/LAMA FDCs and their clinical relevance the same 
across the literature?
Search strategy
This systematic review has been registered in PROSPERO 
(registration number: CRD42017070930; https://www.crd.
york.ac.uk/prospero/display_record.php?RecordID=70930) 
and performed in agreement with the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) 
statement (Figure 1).7 This systematic review satisfied all 
the recommended items reported by the PRISMA-P 2015 
checklist.8
We undertook a comprehensive literature search for RCTs 
published in English and looking at the impact of LABA/
LAMA FDCs in patients with COPD. The search was per-
formed in PubMed, Embase, Scopus, and Google Scholar 
through to September 2017, in order to provide for relevant 
studies available up to September 30, 2017.
The terms “aclidinium,” “formoterol,” “glycopyrronium,” 
“glycopyrrolate,” “indacaterol,” “olodaterol,” “salmeterol,” 
“tiotropium,” “umeclidinium,” and “vilanterol” were searched 
for the FDCs, and the term “chronic obstructive pulmonary 
disease” OR “COPD” was searched for the disease.
Studies reporting the impact of the currently approved 
doses (European Medicines Agency and/or the United States 
Food and Drug Administration dosing) of LABA/LAMA 
FDCs vs LABAs or LAMAs or LABA/inhaled corticosteroid 
(ICS) FDCs on lung function (trough and peak FEV
1
), dysp-
nea (assessed using Transition Dyspnea Index [TDI] scores), 
quality of life (assessed using St George’s Respiratory Ques-
tionnaire [SGRQ] scores), COPD exacerbation rates, exercise 
tolerance (assessed by endurance time [ET]), inspiratory 
capacity (IC), and the use of rescue medication were included 
in this systematic review. Two reviewers independently 
checked the relevant studies identified from literature searches 
and databases. The studies were selected in agreement 
with the previously mentioned criteria, and any difference 
in opinion about eligibility was resolved by consensus.
Quality score
The Jadad score, with a scale of 1–5 (score of 5 being the 
best quality), was used to assess the quality of studies con-
cerning the likelihood of biases related to randomization, 
double blinding, withdrawals, and dropouts.9 Studies were 
considered of high quality if they had a Jadad score $3. Two 
reviewers independently assessed the quality of individual 
studies, and any difference in opinion about the quality score 
was resolved by consensus.
The quality of the publications was assessed in agree-
ment with the Grading of Recommendations Assessment, 














































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1






Data from included studies were extracted and checked for 
study references, RCT registry number, study duration, doses 
of FDCs and comparators, FEV
1
, TDI, SGRQ, COPD exac-
erbations, ET, IC, rescue medication, and Jadad score.
end points
The primary objective of this systematic review was to assess 
the impact of LABA/LAMA FDCs vs comparators on FEV
1
, 
TDI and SGRQ (treatment duration $12 weeks; statistically 
significant improvement vs comparators), COPD exacerba-
tions (treatment duration $52 weeks; statistically significant 
reduction of moderate–severe exacerbation rate and/or risk 
vs comparators and/or statistically significant increase of the 
time to the first exacerbation; exacerbations have been evalu-
ated when included among the outcomes of RCTs and not 
if reported as adverse events [AEs]), ET and IC (treatment 
duration $3 weeks; statistically significant improvement 
vs comparators), and rescue medication (treatment dura-
tion $12 weeks; statistically significant reduction of puff/
day vs comparators). The secondary objective was to assess 
the safety profile of LABA/LAMA FDCs vs comparators.
Strategy for data synthesis
A systematic narrative synthesis was performed on the results 
of the included studies (Table 1),11–37 structured around the 
type of intervention, target population characteristics, type of 
outcome, and intervention content. The superiority of LABA/
LAMA FDCs vs comparators was reported and discussed in 
agreement with the abovementioned criteria.
Results
Of the 62 potentially relevant studies identified in the initial 
search, 27 (44%) studies were deemed eligible for a qualita-
tive analysis (Figure 1); their characteristics are summarized 
in Table 1. All the clinical trials were high-quality studies 
with a Jadad score $3. Patients enrolled in the selected 
clinical trials had to be able to correctly use the inhaler 
devices. Furthermore, the overall comorbidities were com-
parable among the studies. Table 2 shows the synthesis of the 
main pharmacological characteristics of LABAs, LAMAs, 
and ICS in the clinical trials included in this systematic 
review. Table 3 summarizes the studies in which LABA/
LAMA combinations were significantly superior, similar, 
or inferior to comparators.
Figure 1 PRISMA flow diagram for the identification of studies included in the systematic review concerning the impact of LABA/LAMA FDCs in COPD.
Abbreviations: FDCs, fixed-dose combinations; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; PRISMA, the Preferred Reporting Items for 
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LABA/LAMA FDCs were associated with significant 
improvements in the morning predose trough FEV
1
 and peak 
FEV
1
 compared with their LABA or LAMA comparators 
(high quality of evidence, GRADE ++++). These effects 
were maintained over time.
Formoterol/aclidinium was found superior to formoterol, 
but not consistently superior to aclidinium in terms of trough 
FEV
1
,10,12,14,15 whereas the gain in peak FEV
1
 reached with 
formoterol/aclidinium was significant vs both formoterol 
and aclidinium.14,15
Formoterol/glycopyrrolate was found superior to both 
formoterol and glycopyrrolate in improving peak and trough 
FEV
1
;16,17 however, it did not reach superiority vs tiotropium 
in one study.16 Olodaterol/tiotropium was found superior to 
both olodaterol and tiotropium in improving trough FEV
1
;29,30 
however, it did not reach superiority vs tiotropium in one 
study.30 No trials reporting superiority of olodaterol/tiotropium 
for improving peak FEV
1
vs LABA or LAMA monotherapy 
were identified. Both indacaterol/glycopyrronium and 
vilanterol/umeclidinium have shown superiority vs LABA 
(indacaterol and vilanterol, respectively) or LAMA (glyco-
pyrronium and tiotropium or umeclidinium and tiotropium, 
respectively) in terms of improving peak FEV
1
,22,24,34,35,37 as 
well as improving trough FEV
1
.18,19,22,24,25,31,34–37
LABA/LAMA FDCs also showed significant superiority 
in improving trough FEV
1
 and peak FEV
1
vs the LABA/ICS 
comparator salmeterol/fluticasone (SFC; moderate quality 
of evidence, GRADE +++). One trial demonstrated the 
superiority of formoterol/aclidinium to SFC 50/500 µg at 
improving peak FEV
1
; however, superiority in morning pre-
dose FEV
1
 was not reached.13 Four trials showed superiority 
of indacaterol/glycopyrronium vs SFC FDC at improving 
trough FEV
1
,18,20,21,26 while two trials demonstrated superior-
ity of indacaterol/glycopyrronium vs the same LABA/ICS at 
improving peak FEV
1
.21,26 Two trials comparing vilanterol/
umeclidinium with SFC FDC, although at a lower dose in one 
study,33 demonstrated superiority at improving both trough 
FEV
1
 and peak FEV
1
.32,33
No trials comparing the effects of formoterol/glycopyr-
rolate or olodaterol/tiotropium with a LABA/ICS on lung 
function were identified.
TDI
LABA/LAMA FDCs were also associated with a significant 
improvement in TDI scores at 12 weeks compared with their 
LABA or LAMA comparators (high quality of evidence, 
GRADE ++++).
Formoterol/aclidinium was found to be superior to both 
formoterol11,15 and aclidinium in one study11 at improving 
TDI scores from baseline; however, it did not reach superior-
ity vs aclidinium in one study.14 Formoterol/glycopyrrolate 
also demonstrated superiority at improving TDI scores from 
baseline vs formoterol or glycopyrrolate in one trial, but it 
was not superior to tiotropium in the same study.17 Olodat-
erol/tiotropium was found to be superior to olodaterol27,29 or 
tiotropium,27,29,30 and indacaterol/glycopyrronium was found 
to be superior to indacaterol18,22 (except in one study23) or 
LAMAs (glycopyrronium or tiotropium).18,22,24 It must be 
noted that in one trial the LABA and LAMA comparators 
were combined in a single group.18 Vilanterol/umeclidinium 
has not demonstrated to be superiority to vilanterol or umecli-
dinium and/or tiotropium at improving TDI scores, even if 
different trials evaluated this improvement.31,34,37
Compared with an LABA/ICS FDC, LABA/LAMA 
FDCs have shown significant improvements in TDI at 
12 weeks (low quality of evidence, GRADE ++). However, 
when the LABA/LAMA FDCs were analyzed separately, 
important differences between the compounds were 
found. Only indacaterol/glycopyrronium has been shown 
in two trials,18,26 to significantly improve TDI scores (not 
significantly different in one20 vs SFC FDC). Formoterol/
aclidinium13 and vilanterol/umeclidinium32,33 both failed to 
demonstrate superiority vs SFC FDC, even when compared 
with a lower ICS dose in one trial.33
No trials comparing the effects of formoterol/glycopyr-
rolate or olodaterol/tiotropium with a LABA/ICS FDC on 
TDI scores were identified.
SGRQ
LABA/LAMA FDCs had significant improvements in SGRQ 
at 12 weeks compared with their LABA or LAMA compara-
tors (moderate quality of evidence, GRADE +++).
Formoterol/glycopyrrolate was found to be superior at 
improving SGRQ scores to glycopyrrolate monotherapy in 
two trials but was not superior to tiotropium and to formoterol 
monotherapy in the same studies.16,17 Olodaterol/tiotropium 
was found to be superior to both olodaterol29 and tiotropium29,30 
at improving SGRQ scores. Indacaterol/glycopyrronium was 
found to be superior to indacaterol22 or glycopyrronium and/or 
tiotropium22,24,25 at improving SGRQ scores, while vilanterol/
umeclidinium was found to be superior to umeclidinium in 
one study35 (similar to umeclidinium or tiotropium in three 
studies,30,33,36 but not superior to vilanterol).33,36 Formoterol/
aclidinium did not demonstrate superiority vs formoterol or 
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Concerning LABA/LAMA FDCs’ impact on SGRQ 
compared with the LABA/ICS comparator, only indacaterol/
glycopyrronium, in one trial, has demonstrated superiority 
to SFC FDC20 (not significantly superior in two studies).20,25 
No trials comparing the effects of formoterol/glycopyrro-
late or olodaterol/tiotropium with an LABA/ICS FDC on 
SGRQ scores were identified. Formoterol/aclidinium13 and 
vilanterol/umeclidinium32,33 vs SFC FDC failed to demon-
strate superiority, even when compared with a lower ICS 
dose in one trial.33
COPD exacerbations
LABA/LAMA FDCs have shown significant improve-
ments in the rate of moderate/severe COPD exacerbations 
over 52 weeks compared with LAMA or LABA/ICS FDC 
(very low quality of evidence, GRADE +). However, of the 
LABA/LAMA FDCs, only indacaterol/glycopyrronium has 
demonstrated superiority to both an LAMA (glycopyrro-
nium, not statistically different vs tiotropium)25 and LABA/
ICS FDC (SFC)20 in the reduction of exacerbation rates. 
No trials comparing the effects of formoterol/aclidinium, 
vilanterol/umeclidinium, formoterol/glycopyrrolate, or 
olodaterol/tiotropium with any of the LABA, LAMA, or 
LABA/ICS FDC on moderate/severe exacerbation rates 
were identified.
exercise tolerance and IC
Olodaterol/tiotropium has demonstrated superiority to 
olodaterol or tiotropium monotherapy at improving isotime 
IC and superiority to olodaterol monotherapy at improv-
ing ET,28 while indacaterol/glycopyrronium significantly 
improved isotime IC vs tiotropium23 (moderate quality of 
evidence, GRADE +++). No published trials comparing the 
effects of formoterol/aclidinium, vilanterol/umeclidinium, or 
formoterol/glycopyrrolate with any of the LABA, LAMA, 
or LABA/ICS FDCs on ET or IC were identified.
Rescue medication use
LABA/LAMA FDCs showed significant improvements 
on the use of rescue medication over 12 weeks com-
pared with LABA or LAMA (high quality of evidence, 
GRADE ++++).
Formoterol/glycopyrrolate was superior to formoterol16 
(but not superior in one study)16 or glycopyrrolate and/or 
tiotropium,16,17 indacaterol/glycopyrronium was superior to 
indacaterol18,22,24 (not significantly different in one study)18 
as well as to glycopyrronium and/or tiotropium,18,22,24,25 
and olodaterol/tiotropium was superior to olodaterol29 or 
tiotropium29 at reducing the need for rescue medications at 
12 weeks. Formoterol/aclidinium was superior to aclidinium 
in two studies,13,14 but not in another one,10 nor was superior to 
formoterol at improving rescue medication use.14,15 Similarly, 
vilanterol/umeclidinium was superior to tiotropium and/or 
umeclidinium, but not superior to vilanterol at improving 
rescue medication use.31,34,35,37
Compared with LABA/ICS FDCs, LABA/LAMA FDCs 
significantly improved rescue medication use at 12 weeks 
overall; however, differences between LABA/LAMA 
FDCs compounds were found (low quality of evidence, 
GRADE ++). Only indacaterol/glycopyrronium in three 
studies18,20,26 (not in one)20 and vilanterol/umeclidinium in 
one study32 demonstrated superiority vs SFC FDC (not in 
another study)31 at improving rescue medication use (it must 
be noted that in one trial the dose of SFC was 50/250).33 One 
trial comparing formoterol/aclidinium with an SFC FDC13 
did not find any significant improvements in rescue medica-
tion use at 12 weeks. No studies comparing the effects of 
formoterol/glycopyrrolate or olodaterol/tiotropium with an 
LABA/ICS FDC on rescue medication use were identified.
Safety
LABA/LAMA FDCs are a safe therapeutic approach in 
patients with COPD. Current literature shows that combin-
ing an LABA with an LAMA does not increase the risk of 
AEs or serious AEs (SAEs) compared with their individual 
components.5,38 Furthermore, LABA/LAMA FDCs have 
been shown to have a comparable safety profile to LABA/
ICS FDCs.5
LABA/LAMA FDCs also do not significantly increase the 
risk of cardiovascular SAEs compared with their individual 
components.9 Intriguingly, some of the LABA/LAMA FDCs 
showed a numerical trend in protecting against cardiovas-
cular SAEs, whereas other combinations showed a signal in 
increasing the risk of cardiovascular SAEs.9 The frequencies 
of SAEs and deaths in RCTs of LABA/LAMA FDCs are low. 
However, while COPD makes it difficult to perform studies 
that are adequately powered to detect the real safety profile 
of LABA/LAMA FDCs, it appears that the cardiac safety 
of LAMA/LABA FDCs could be lower in COPD patients 
who have concomitant cardiovascular diseases, prolonged 
corrected QT interval, or polypharmacy.39
In any case, we have to highlight that the occurrence of 
rare/uncommon SAEs may be related to several individual 
patient characteristics and that COPD patients with comor-
bidities are usually excluded from RCTs. In fact, a recent 
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who added an LAMA to an LABA, or vice versa, indicated 
that adding a second long-acting bronchodilator does not 
increase the risk of most cardiovascular events in the real-
world-setting treatment of COPD. However, the authors 
detected a modest, although significant, increase in the risk of 
heart failure.40 To confirm these data from meta-analyses and 
observational studies, high-quality, large, RCTs including 
patients with COPD and cardiovascular comorbidities are 
warranted.39
Moreover, also the drug formulations and the character-
istics of the specific devices may modulate the frequency of 
SAEs and lead to potential imbalance of the safety profile 
in favor of some LABA/LAMA FDCs rather than others.41,42 
In fact, while some inhaler devices deliver fine particles leading 
to increased lung deposition, others deliver greater particles 
that induce oropharyngeal deposition of drugs. The latter 
condition may result in a greater systemic absorption of 
bronchodilators, with a potential increased risk of AEs.41,42
Discussion
The main aim of this systematic review was to investigate 
whether the evidence for the efficacy and safety of all mar-
keted LABA/LAMA FDCs or those under development is 
comparable, in terms of the number of RCTs and outcomes. 
We found that evidence supporting the use of different 
LABA/LAMA FDCs for the management of COPD is 
heterogeneous.
In the era of evidence-based medicine, we rely on the 
literature to identify the best approach to treat patients, 
and systematic reviews are a valuable tool to define a clear 
picture of current literature on LABA/LAMA FDCs. Several 
systematic reviews and meta-analyses have been conducted 
and published regarding the effect of the LABA/LAMA class 
on different outcomes such as changes in FEV
1
, patient-
reported outcomes, and safety,5,9,43,44 but none of them was 
focused on producing a tool to easily identify which (if not 
all) LABA/LAMA FDCs have demonstrated superior results 
when compared with single bronchodilators (LABA or 
LAMA) or LABA/ICS. If the goal of treatment is, eg, to 
reduce dyspnea, using the results of this systematic review, 
we can now choose which FDC has shown to improve this 
outcome; again, if the focus is to reduce exacerbations, we 
can easily find the right answer to this question in the results 
of this review.
Overall, LABA/LAMA FDCs have shown superior-
ity regarding lung function improvement vs comparators. 
However, at difference with others, indacaterol/glycopyr-
ronium and vilanterol/umeclidinium were the only FDCs 
demonstrating statistical superiority vs LABA and LAMA 
monotherapies and LABA/ICS in terms of improvements 
in trough FEV
1
, which is the most commonly investigated 
(and requested by health authorities) outcome in studies 
on COPD.
Regarding TDI improvement, indacaterol/glycopyrronium 
has shown superior results vs each comparator, but surpris-
ingly vilanterol/umeclidinium did not show any superi-
ority vs LABA or LAMA or LABA/ICS FDCs, even if 
many trials evaluated this outcome. Similarly, significant 
improvements in SGRQ scores were only demonstrated 
with indacaterol/glycopyrronium, while other LABA/LAMA 
FDCs (particularly formoterol/aclidinium and vilanterol/
umeclidinium) showed no advantage over LABA, LAMA, 
or LABA/ICS FDCs.
One of the biggest differences between the different 
LABA/LAMA FDCs is their effect on COPD exacerbation 
rates, with only indacaterol/glycopyrronium demonstrat-
ing superiority at improving COPD exacerbation rates vs 
LAMA or LABA/ICS FDCs. One Cochrane review found a 
significant heterogeneity analyzing this outcome for different 
LABA/LAMA FDCs and concluded that it is still not clear 
whether only indacaterol/glycopyrronium prevents COPD 
exacerbations or all LABA/LAMA FDCs are able to prevent 
these events.45 In our opinion, studies investigating the superi-
ority of LABA/LAMA FDCs at preventing COPD exacerba-
tions vs LABA monotherapy are not needed as it is already 
proven that LAMAs46,47 and LABA/ICS FDCs48 are superior 
to LABAs for this outcome. As indacaterol/glycopyrronium 
demonstrated better exacerbation prevention vs both LAMA 
(glycopyrronium) and LABA/ICS (SFC), the demonstration 
of superiority vs any LABA seems to be irrelevant.
Regarding exercise tolerance and isotime IC, more data 
supporting LABA/LAMA FDCs are needed as this is an 
important outcome impacting the quality of life of COPD 
patients. Olodaterol/tiotropium has shown superiority vs 
LABA regarding isotime IC and ET, while indacaterol/
glycopyrronium was superior to LAMA regarding isotime 
IC. Actually, a pairwise and network meta-analysis conducted 
by Calzetta et al documented that LABA/LAMA combina-
tion was superior to the monocomponents in increasing both 
ET and IC, providing support to the double bronchodilation 
strategy for the increase of exercise tolerance in COPD 
patients.43 One suggestion for future trials is to combine 
double bronchodilation and exercise training; this could bring 
superior results in terms of ET. Actually, as shown by Ofir 
et al49 COPD patients often stop exercise for leg discomfort, 
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may result in prolonging exercise duration or shifting the 
locus of symptom limitation from dyspnea to leg fatigue. 
As such, combining exercise training (to improve limb muscle 
fatigue) with double bronchodilation may produce superior 
results in terms of exercise tolerance for COPD patients.
We were able to detect some differences between differ-
ent LABA/LAMA FDCs; in fact, some LABA/LAMA FDCs 
showed significant benefits on specific outcomes, but several 
inconsistencies in the evidence supporting the efficacy of 
LABA/LAMA FDCs were found; these were likely caused 
by differences in study design, comparators, outcomes, and 
patient populations or by differences existing between the 
LABA/LAMA FDCs. Being aware of these differences allows 
us to choose the FDC that has been shown to improve a spe-
cific outcome that appears to be critical in a given patient.
The 2018 GOLD Report recommends the use of two 
bronchodilators for Group B patients with persistent 
breathlessness on monotherapy and Group C patients with 
persistent exacerbations, and indicates LABA/LAMA com-
binations as preferred treatment in Groups D patients.50 The 
present systematic review supports the GOLD algorithm, 
as LABA/LAMA FDCs have shown superiority vs any 
comparators for the vast majority of evaluated outcomes; 
yet, the step-up strategy recommended by the GOLD report 
is supported by this systematic review for the same reason. 
The superiority shown by some LABA/LAMA FDCs vs 
LABA/ICSs for the majority of evaluated outcomes is 
supporting the GOLD 2018 report, as current evidence is 
in favor of the double bronchodilation strategy for both 
efficacy and safety reasons. As acknowledged by the GOLD 
committee, long-term treatment with ICS (especially fluti-
casone) could be associated with the risk of pneumonia and 
other adverse effects. Therefore, LABA/LAMA seems an 
overall safer and more effective option for COPD patient 
management.
Potentially an early start with a fast-acting LABA/LAMA 
FDC at the time of COPD diagnosis could lead to rapid 
improvements in symptoms. Prompt symptom relief will 
give reassurance of effectiveness and could be a key factor 
in patient compliance, thus likely improving adherence 
to the prescribed medications that are usually very low in 
COPD patients, with a negative influence on outcomes. This 
approach is supported by the GOLD 2018 report that states 
that, for patients with severe breathlessness, initial therapy 
with two bronchodilators may be considered.50
The focus of this study was to compare the LABA/LAMA 
FDC in COPD patients, and the results must be interpreted in 
the light of the population enrolled in these trials. Of course, 
in asthmatic and ACO patients, an accurate evaluation of an 
ICS-containing regimen is mandatory.
From a safety standpoint, the current evidence suggests 
that LABA/LAMA FDCs are a safe therapeutic approach 
in COPD patients. While the choice of a specific LAMA/
LABA FDC should not be based on the specific safety profile, 
postmarketing surveillance and observational studies are wel-
comed to adequately clarify the safety of any LABA/LAMA 
FDC in daily clinical practice. A recent study on 284,220 
LABA–LAMA-naïve patients with COPD has shown an 
increased risk of a severe cardiovascular disease event within 
30 days of initiation of LABA or LAMA therapy.51 However, 
the risk was reduced in the longer term. Therefore, this study 
highlights the importance of a careful early management of 
COPD after the introduction of LABA or LAMA therapy.
We did not perform any meta-analysis to compare the 
different LABA/LAMA FDCs as it was not the objective 
of the study. In our opinion, a statistically significant differ-
ence vs comparators could help to establish the superiority 
of one treatment over another, given the lack of universally 
accepted clinically relevant differences between active 
treatments. However, it must be pointed out that statistically 
significant superiority does not always mean difference in 
clinical relevance.
Finally, although no further studies could formally be 
considered in this systematic review as the methodological 
criteria already registered in PROSPERO (CRD42017070930) 
set the literature search at the end of September 2017, we 
cannot overlook recent RCTs on triple FDC therapy including 
an ICS plus an LABA plus an LAMA, such as the TRIBUTE 
and IMPACT studies,52,53 which provided relevant findings 
concerning the efficacy and safety of adding an ICS to the 
double bronchodilation therapy in the management of COPD 
patients. Interestingly, the triple therapy demonstrated a 
greater protective effect against COPD exacerbations in 
patients with higher blood eosinophil levels, as further con-
firmed by the SUNSET study54 that aimed to evaluate the 
impact of de-escalation from the long-term triple therapy to 
indacaterol/glycopyrronium in nonfrequently exacerbating 
COPD patients.
Conclusion
Evidence supporting the efficacy of different LABA/LAMA 
FDCs and their clinical relevance for the management of 
COPD are heterogeneous across the literature, particularly 
for improvements in TDI and SGRQ scores, and even 
more for exacerbation prevention, and changes in ET and 
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superiority over LABA/ICS for most of the evaluated out-
comes. Based on the published evidence, the equivalence of 
all LABA/LAMA FDCs cannot be established. Indacaterol/
glycopyrronium is so far the LABA/LAMA combination sup-
ported by the more robust evidence of superiority vs LABA, 
LAMA, and LABA/ICS across the evaluated outcomes.
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